Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Heart Lung Circ ; 23(3): 234-41, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24268488

RESUMEN

BACKGROUND: Ventricular assist device (VAD) implantation has become an effective option for patients with severe heart failure. However, device-related infections remain a significant problem. The aim of this study was to describe the incidence and microbiological aetiology of bacteraemia in patients with VADs, and to assess the impact of bacteraemia on clinical outcomes. METHODS: A retrospective study was conducted of patients having VAD implantation at the Alfred Hospital (Melbourne, Australia) from October 1990 to July 2009. Medical records and microbiology databases were reviewed. Patients who were supported with a VAD for 72h or more were evaluated for demographic data, VAD type, the occurrence of bacteraemia and clinical outcomes. RESULTS: During the 19-year period, 135 VAD patients (89 Thoratec PVAD, 10 Novacor, and 36 Ventrassist) supported for a total duration of 17,304 (median 74) support days were included. Sixty-one patients (45%) developed VAD-associated bacteraemia, an incidence of 5.6 episodes per 1000 support days. The incidence of bacteraemia per 1000 days of support was similar for the three devices used: Thoratec PVAD, Novacor and Ventrassist VADs (7.8±0.8, 5.2±1.5 and 3.4±0.5, respectively, p=0.74). Staphylococcus aureus was the most common pathogen (25%). The rates of death on device, survival to transplant, recovery with explant and outcomes after transplantation, including 30-day mortality, median survival time and incidence of cerebrovascular accidents were not significantly impacted upon by bacteraemia. CONCLUSIONS: Bacteraemia is common in VAD patients. However, the incidence of VAD-associated bacteraemia is independent of device type and with aggressive antimicrobial therapy; clinical outcomes need not be affected by the bacteraemia.


Asunto(s)
Antibacterianos/administración & dosificación , Bacteriemia , Corazón Auxiliar/efectos adversos , Registros Médicos , Infecciones Estafilocócicas , Staphylococcus aureus , Adolescente , Adulto , Anciano , Bacteriemia/tratamiento farmacológico , Bacteriemia/etiología , Bacteriemia/mortalidad , Supervivencia sin Enfermedad , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/etiología , Infecciones Estafilocócicas/mortalidad , Tasa de Supervivencia
2.
Transl Lung Cancer Res ; 13(2): 434-442, 2024 Feb 29.
Artículo en Inglés | MEDLINE | ID: mdl-38496692

RESUMEN

Background: Tyrosine kinase inhibitors (TKIs) have changed the treatment landscape for patients with advanced non-small cell lung cancer (NSCLC) found to have oncogene-driven activating epidermal growth factor receptor (EGFR) mutations. Whilst there have been a handful of case reports of sensitivity to first-generation TKIs in EGFR L861R mutations, the efficacy of the third-generation TKI osimertinib in NSCLC patients with EGFR L861R and EGFR exon 18 deletion-insertion mutations is limited. Case Description: We report two patients from our institution with uncommon EGFR mutations treated with first-line osimertinib. Our first patient, a 72-year-old male with metastatic lung adenocarcinoma was identified to harbour a rare EGFR L861R mutation and was commenced on osimertinib. After a follow-up period of 18 months, the patient is continuing to experience treatment benefit with imaging showing a good partial response. The second patient, a 60-year-old male also with metastatic lung adenocarcinoma and an EGFR exon 18 deletion-insertion mutation achieved a partial response for 6.6 months. Upon progression, he was commenced on carboplatin and pemetrexed chemotherapy however died from subsequent pneumonia. He had an overall survival (OS) from time of diagnosis of 7.6 months. Conclusions: We demonstrate clinical efficacy of first-line osimertinib in the treatment of advanced NSCLC harbouring uncommon EGFR L861R and EGFR exon 18 deletion-insertion mutations. These results may be suggestive of the wider applicability of osimertinib in the treatment of uncommon EGFR mutant NSCLC.

3.
J Med Imaging Radiat Oncol ; 65(6): 728-730, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33410239

RESUMEN

Caesarean scar ectopic pregnancies are rare but growing in incidence due to increasing rates of caesarean deliveries. These cases have historically been treated with either medical or surgical management which both have significant limitations. More recently, uterine artery embolisation (UAE) has shown significant promise in the treatment of this condition. We present the case of a complex patient with a caesarean scar ectopic successfully managed with combined UAE and surgery.


Asunto(s)
Abortivos no Esteroideos , Embarazo Ectópico , Cesárea/efectos adversos , Cicatriz/diagnóstico por imagen , Femenino , Humanos , Metotrexato , Embarazo , Embarazo Ectópico/diagnóstico por imagen , Embarazo Ectópico/cirugía , Radiología Intervencionista
4.
J Med Imaging Radiat Oncol ; 65(6): 737-739, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33547764

RESUMEN

Case report of an atypical location of ACP. ACP should be considered even in small joints with characteristic imaging even with trauma involvement.


Asunto(s)
Calcinosis , Periartritis , Calcinosis/diagnóstico por imagen , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA